Regeneron CEO: Anticipating PCSK9 launch, but worried about pricing debate

Regeneron ($REGN) is charging toward an FDA submission for its cholesterol-fighting drug candidate alirocumab. And in hopes of approval, it's working on launch plans with partner Sanofi ($SNY). But in the meantime, CEO Leonard Schleifer says he's worried that the brouhaha over drug prices might undermine Regeneron's pricing power. Report

Suggested Articles

Eli Lilly bought full-page ads in more than a dozen newspapers in the U.S. to let people with diabetes who use Lilly drugs to know help is available.

Only months after a game-changing new approval for Vascepa, Amarin has lost a key fight over its patents—and now it's scrambling to respond.

Move over, Roche. There’s a new small cell lung cancer therapy on the scene, and it belongs to AstraZeneca.